Clinical trial
Pulmonary Hypertension: Assessment of Cell Therapy
NCT00469027 · Northern Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00469027 |
|---|---|
| Title | Pulmonary Hypertension: Assessment of Cell Therapy |
| Official title | Phase I Trial to Establish Safety of Autologous Progenitor Cell-based Gene Therapy Delivery of heNOS in Patients With Severe Pulmonary Arterial Hypertension(PAH)Refractory to Conventional Treatment |
| Acronym | PHACeT |
| Lead sponsor | Northern Therapeutics, Industry |
| Collaborators | Unity Health Toronto Sir Mortimer B. Davis - Jewish General Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hypertension, Pulmonary |
| Intervention type | Biological |
| Interventions | eNOS transfected EPCs will be delivered via a PA line |
| Enrollment | 7 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | May 4, 2007 |
| Last update posted | Oct 17, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: